Journal
ANTICANCER RESEARCH
Volume 37, Issue 12, Pages 6533-6540Publisher
INT INST ANTICANCER RESEARCH
DOI: 10.21873/anticanres.12109
Keywords
Breast cancer; androgen receptor (AR); estrogen receptor alpha (ER alpha); triple-negative breast cancer (TNBC); review
Categories
Ask authors/readers for more resources
Breast cancer (BrCa) is the most common malignancy among women worldwide, and one of the leading causes of cancer-related deaths in females. Despite the development of novel therapeutic modalities, triple-negative breast cancer (TNBC) remains an incurable disease. Androgen receptor (AR) is widely expressed in BrCa and its role in the disease may differ depending on the molecular subtype and the stage. Interestingly, AR has been suggested as a potential target candidate in TNBC, while sex hormone levels may regulate the role of AR in BrCa subtypes. In the presence of estrogen receptor alpha (ERa), AR may antagonize the ERa-induced effects, whereas in the absence of estrogens, AR may act as an ER alpha-mimic, promoting tumor. Thus, depending on the BrCa microenvironment, both agonists and antagonists of the AR have been suggested as therapeutic approaches. Herein, we review the role of AR signaling in BrCa and the molecular cross-talk mechanisms with other molecules/ pathways, as well as its therapeutic implications in the different subtypes of the disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available